Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Citius Pharmaceuticals (CTXR) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Leonard Mazur will present on September 10, 2024, at 9:00 am ET at the Lotte New York Palace Hotel and host one-on-one investor meetings.

Key business developments to be discussed include:

• FDA approval of LYMPHIR™ for cutaneous T-cell lymphoma treatment
• Merger of a subsidiary with TenX Keane, forming Citius Oncology (CTOR)
• Successful Phase 3 Pivotal Trial of Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections

Investors can register on the conference website and join the live webcast presentation.

CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET

CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City.

H.C. Wainwright Conference Details:               

Presentation:	9:00 am ET on Tuesday, September 10, 2024*
Location:	Lotte New York Palace Hotel, New York City
Registration:	Available on the conference website.
1x1 meetings:	Requests available upon registration or by contacting Citius Investor Relations.
Webcast:	Join live here.

*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.

Recent Business Developments:

During his presentation and investor meetings, Mr. Mazur will discuss recent business developments including:

• FDA Approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL);
• Merger of the Company's subsidiary with TenX Keane to form publicly listed Citius Oncology, Inc. (Nasdaq: CTOR); and,
• Achieving primary and secondary endpoints in the completed Phase 3 Pivotal Trial of Mino-Lok^®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns approximately 90% of Citius Oncology. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com 
908-967-6677 x113

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239745.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When is Citius Pharmaceuticals (CTXR) presenting at the H.C. Wainwright Conference?

Citius Pharmaceuticals (CTXR) is presenting on Tuesday, September 10, 2024, at 9:00 am ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

What recent FDA approval will Citius Pharmaceuticals (CTXR) discuss at the conference?

Citius Pharmaceuticals (CTXR) will discuss the recent FDA approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL).

What is the status of Citius Pharmaceuticals' (CTXR) Mino-Lok® Phase 3 trial?

Citius Pharmaceuticals (CTXR) has completed the Phase 3 Pivotal Trial of Mino-Lok®, achieving both primary and secondary endpoints. Mino-Lok® is an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections.

What recent merger will Citius Pharmaceuticals (CTXR) address at the H.C. Wainwright Conference?

Citius Pharmaceuticals (CTXR) will address the recent merger of its subsidiary with TenX Keane, which resulted in the formation of publicly listed Citius Oncology, Inc. (Nasdaq: CTOR).